Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: POLBF )

0.1150 UNCHANGED
Last Price Updated: 9:30 AM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about POLBF

< Previous 1 2 Next >
Poolbeg Pharma PLC Announces Board Appointment
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Results of Annual General Meeting
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Annual Report & AGM Notice
Via ACCESSWIRE
Poolbeg Pharma "in a very healthy cash position" after first full year of operations
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after publishing final results for 2022 that show that the clinical-stage biotech company finished its first full... 
Via TheNewswire.com
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022
Via ACCESSWIRE
Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human... 
Via TheNewswire.com
Poolbeg Pharma PLC Announces Strategic Expansion of POLB 001 into Oncology
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial
Via ACCESSWIRE
Poolbeg Identifies Novel RSV Drug Candidates
Via ACCESSWIRE
Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing the data readout from an LPS human challenge trial for POLB 001, the infectious... 
Via TheNewswire.com
Poolbeg Pharma "really open" to different types of deal for POLB 001
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) VP of Business Development David English speaks to Proactive's Thomas Warner about the work he's doing to progress the clinical stage infectious disease... 
Via TheNewswire.com
Poolbeg Pharma announces expansion of POLB 001 into oncology
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing that the company has submitted a patent application for the use of POLB 001 in a... 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
Poolbeg Pharma upbeat on preliminary influenza drug results
Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential... 
Via TheNewswire.com
Poolbeg Pharma PLC Announces Metabolic Diseases Oral Delivery Licence Signed
Via ACCESSWIRE
Poolbeg Pharma PLC - POLB 001 LPS Human Challenge Trial Completed
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Influenza AI model build completed
Via ACCESSWIRE
Poolbeg-led Consortium Awarded EUR 2.3m Grant
Via ACCESSWIRE
Poolbeg Pharma PLC Announces AI Programme Yields Novel RSV Drug Targets
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Capital Markets Day
Via ACCESSWIRE
Poolbeg Pharma PLC Announces CEO Share Purchase
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 US Patent update
Via ACCESSWIRE
Poolbeg Licence of Melioidosis Vaccine Candidate
Via ACCESSWIRE
Poolbeg Pharma PLC Announces HC Wainwright Global Investment Conference
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Appointment of Joint Broker
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB001 Human Challenge Clinical Trial To Commence
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Appointment of Joint Broker
LONDON, UK / ACCESSWIRE / July 29, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light... 
From Poolbeg Pharma PLC
Via AccessWire
Poolbeg Pharma PLC Announces POLB001 Human Challenge Clinical Trial To Commence
Major milestone reached as POLB 001 human challenge clinical trial ready to commence 
From Poolbeg Pharma PLC
Via AccessWire
Poolbeg Pharma PLC Announces Project update for AI model of RSV data
OneThree Biotech completes build and optimisation of AI model for RSV data - results to come in H2 
From Poolbeg Pharma PLC
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Poolbeg Pharma PLC Announces US Patents Granted for POLB 001 and POLB 002
Further Expansion of IP Portfolio Enhancing Protection of Poolbeg's Growing Pipeline 
From Poolbeg Pharma PLC
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Poolbeg Pharma PLC - GMP Manufacturing Contract Signed
Update on POLB 001 Clinical Development GMP manufacturing contract signed ensuring ample supply of POLB 001 for clinical development and for use in investigating further potential disease indications... 
From Poolbeg Pharma PLC
Via AccessWire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.